Evidence · idea-018

What the narrowing buys, stated as the regulatory claim it is: an intended use confined to the indications named in 21 CFR 890.5870 (fracture-fixation adjunct, spinal-fusion adjunct, established nonunion or failed fusion) falls inside the reclassified generic type and is reachable by 510(k), whereas an intended use claiming acceleration of healing of fresh or acute fractures, or general promotion of bone formation, falls outside it and would require a De Novo or a PMA

A DME MAC Local Coverage Article titled "Osteogenesis Stimulators — Policy Article", article ID A52513, exists in the CMS Medicare Coverage Database and sets documentation and coverage conditions applicable to these HCPCS codes

HCPCS Level II code E0747 exists with the descriptor "Osteogenesis stimulator, electrical, non-invasive, other than spinal applications"

HCPCS Level II codes E0748 ("Osteogenesis stimulator, electrical, non-invasive, spinal applications") and E0760 ("Osteogenesis stimulator, low intensity ultrasound, non-invasive") exist alongside E0747

TAM leg 1 (volume, the checkable leg): the annual number of Medicare fee-for-service allowed services for HCPCS E0747 nationally is on the order of low tens of thousands per year

TAM leg 2 (price): the Medicare DMEPOS fee schedule purchase allowance for one E0747 device is in the low thousands of US dollars

TAM leg 3 (addressable share, and the narrowed denominator): the launch indication's denominator is not US fractures but the subset that progresses to an established, radiographically confirmed nonunion of a long bone, excluding skull, vertebral and tumor-associated nonunions; the Generator estimates this at roughly 5-10% of an annual US fracture volume on the order of six million, i.e. a target population one to two orders of magnitude smaller than the fresh-fracture population the broad indication would have reached

What the narrowing costs, commercially: confining the launch indication to non-spinal established nonunion gives up the spinal-fusion adjunct indication billed under HCPCS E0748, which NCD 150.2 separately covers for high-risk pseudarthrosis patients (claim 8) and which the Generator believes is a larger annual Medicare DME line than E0747

Non-invasive bone growth stimulators are currently marketed in the US by Orthofix (product names "Physio-Stim" and "Spinal-Stim"), Zimmer Biomet (product name "OrthoPak"), and Bioventus (ultrasonic, product name "EXOGEN")

The 510(k) route described in claims 1, 2 and 5 became available on the same date to every incumbent named in claim 19 and to every other entrant, so the pathway itself confers no exclusivity on this candidate

Federal Register document 2026-16368 (91 FR 51710) limits eligibility for the RAPID coverage pathway to class II and class III FDA Breakthrough-designated devices, requires entry at the IDE presubmission stage with devices already market-authorized or already under an IDE excluded, and requires the device to be separately payable — so a device launching by 510(k) on an existing predicate, without a Breakthrough designation, is outside that eligibility

A device dispensed to a Medicare beneficiary by a DMEPOS supplier and paid under HCPCS E0747 is billed and paid in its own right rather than absorbed into a facility or episode payment

The published clinical evidence base for pulsed electromagnetic field stimulation specifically in established nonunion — as distinct from fresh fractures — was not retrieved by the Generator this pass, and no trial, systematic review or PMID is named here in either direction

FTO: no patent search of any kind was performed for this candidate — not for the PEMF waveform or coil geometry, not for the garment-integrated coil form factor, and not for the tamper-evident adherence-logging and compliance-reporting function. The FTO field is unexamined, and no patent number or family is named here because none was found

FTO, second and narrower: whether Orthofix, Zimmer Biomet, Bioventus or Enovis hold live, enforceable US patents covering non-invasive bone growth stimulator waveforms, coil designs, or treatment-compliance monitoring applicable to a nonunion-indicated PEMF device is unknown to the Generator; the underlying PEMF bone-healing art dates to the 1970s and 1980s and the foundational patents from that era would be long expired on any ordinary term, but no specific patent, family, assignee record or expiry date was located or checked

Assumption, not a fact: the idea depends on orthopaedic trauma surgeons being willing to prescribe a new-entrant bone growth stimulator for an established nonunion in preference to the incumbent brands named in claim 19, which have decades of prescriber familiarity and established DMEPOS distribution. There is no connector for prescriber preference and no primary research behind this belief; it is stated explicitly as an assumption so it stays visible to the Scorer and Verifier rather than being phrased as a fact

Assumption, not a fact: the idea depends on patients with an established nonunion wearing the device for the prescribed number of hours per day over a multi-month course, and on a low-profile garment-integrated coil materially improving that adherence relative to existing form factors. No adherence data for existing bone growth stimulators was retrieved and none is cited; stated explicitly as an assumption

Assumption, not a fact: the idea depends on DMEPOS suppliers and payers treating an onboard, tamper-evident device-generated adherence log as materially useful documentation — for continued-coverage support, for audit defence, or for denial reduction — rather than as a feature nobody pays for. Nothing in claim 12's policy article was read, and no supplier or payer was consulted; stated explicitly as an assumption because it is the entire commercial case for the one differentiating feature in mechanism